MADISON, N.J., Aug. 20, 2004

MADISON, N.J., Aug. 20, 2004 Wyeth announced today that the jury in the case of Linda Berntson and Janice Connell v. Wyeth, et al. rendered its decision, finding in favor of the Company in the case brought by Ms. Berntson, while finding in favor of Ms. Connell in her case.

The jury originally awarded Ms. Connell compensatory damages in the
amount of $50,000; however, the parties have agreed to a settlement for an
undisclosed amount. The jury’s verdict with regard to Ms. Berntson has ended
that case.

The verdict came at the end of the first phase of a bifurcated (two phase)
trial that began on August 17, 2004 before The Honorable Alfred J. DiBona, Jr.
in the Court of Common Pleas of the First Judicial District of Pennsylvania.
Plaintiffs alleged heart valve injury from the use of the diet drugs Pondimin
and Redux, drugs once marketed by Wyeth.

The first phase sought to determine whether the plaintiffs were injured as
the result of using Pondimin and Redux, and if so the amount of the damages.
The second phase would have determined liability.

Wyeth is one of the world’s largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery, development,
manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology
products and nonprescription medicines that improve the quality of life for
people worldwide. The Company’s major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Scroll to Top